Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial-Reference-Cited by-同舟云学术

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Published:2022-01 Issue:1 Volume:23 Page:91-103
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Jacobson Caron A,Chavez Julio C,Sehgal Alison R,William Basem M,Munoz Javier,Salles Gilles,Munshi Pashna N,Casulo Carla,Maloney David G,de Vos Sven,Reshef Ran,Leslie Lori A,Yakoub-Agha Ibrahim,Oluwole Olalekan O,Fung Henry Chi Hang,Rosenblatt Joseph,Rossi John M,Goyal Lovely,Plaks Vicki,Yang Yin,Vezan Remus,Avanzi Mauro P,Neelapu Sattva S

Funder

Kite Pharma Inc

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Follicular lymphoma: 2018 update on diagnosis and management;Freedman;Am J Hematol,2018

2. The evolving role of targeted biological agents in the management of indolent B-cell lymphomas;Wang;Ther Adv Hematol,2017

3. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma;Maurer;Am J Hematol,2016

4. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study;Casulo;J Clin Oncol,2015

5. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma;Dreyling;J Clin Oncol,2017

Cited by 229 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focused ultrasound-assisted delivery of immunomodulating agents in brain cancer;Journal of Controlled Release;2024-03

2. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines;Blood Advances;2024-02-13

3. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

4. Ocular toxicities in chimeric antigen receptor T-cell therapy: a real-world study leveraging FAERS database;Immunotherapy;2024-02

5. Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018;Transplantation and Cellular Therapy;2024-02